ATE382370T1 - Antikörper-serumprotein hybride - Google Patents
Antikörper-serumprotein hybrideInfo
- Publication number
- ATE382370T1 ATE382370T1 AT99954209T AT99954209T ATE382370T1 AT E382370 T1 ATE382370 T1 AT E382370T1 AT 99954209 T AT99954209 T AT 99954209T AT 99954209 T AT99954209 T AT 99954209T AT E382370 T1 ATE382370 T1 AT E382370T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- serum protein
- protein hybrid
- hybrid
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9824632.5A GB9824632D0 (en) | 1998-11-10 | 1998-11-10 | Biological compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE382370T1 true ATE382370T1 (de) | 2008-01-15 |
Family
ID=10842195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99954209T ATE382370T1 (de) | 1998-11-10 | 1999-11-10 | Antikörper-serumprotein hybride |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7105160B1 (de) |
| EP (2) | EP1128847B1 (de) |
| AT (1) | ATE382370T1 (de) |
| AU (1) | AU1062700A (de) |
| DE (1) | DE69937899T2 (de) |
| ES (1) | ES2299268T3 (de) |
| GB (1) | GB9824632D0 (de) |
| WO (1) | WO2000027435A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| US20040220086A1 (en) * | 2001-10-17 | 2004-11-04 | Faulk W. Page | Methods and materials for targeting and affecting selected cells |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| EP1888640B1 (de) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Verbesserte nanokörper gegen tumornekrosefaktor-alpha |
| EP2557090A3 (de) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR |
| WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| CA2731617A1 (en) | 2008-07-22 | 2010-01-28 | Maria Joao Saraiva | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| US8748581B2 (en) | 2009-04-10 | 2014-06-10 | Ablynx N.V. | Anti-IL-6R polypeptides and pharmaceutical compositions thereof |
| SG176095A1 (en) | 2009-06-05 | 2011-12-29 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| EP2507262A1 (de) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen |
| EP2513145B1 (de) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Antikörper mit einzelner variabler domäne gegen ox40l, konstrukte und therapeutische verwendung |
| WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| EP4234698A3 (de) | 2010-05-06 | 2023-11-08 | Novartis AG | Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6) |
| BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
| EP3546483A1 (de) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biologische stoffe im zusammenhang mit her3 |
| EP2638068B1 (de) | 2010-11-08 | 2018-12-26 | Novartis AG | Cxcr2 bindende polypeptide |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| EP3252075A1 (de) | 2011-11-04 | 2017-12-06 | Novartis AG | Halbwertszeitverlängererkonstrukte aus low-density-lipoprotein-verwandtem protein 6 (lrp6) |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| EP3630818A1 (de) | 2017-06-02 | 2020-04-08 | Ablynx NV | Aggrecanbindende immunglobuline |
| CA3082280A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
| EP3740507A4 (de) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | Einzeldomänenantikörper und varianten davon gegen pd-1 |
| WO2019185040A1 (en) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against lag-3 and uses thereof |
| IL305301A (en) | 2021-02-19 | 2023-10-01 | Us Health | Single domain antibodies neutralizing SARS CoV-2 |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749570A (en) * | 1981-12-31 | 1988-06-07 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
| US4751286A (en) * | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
| WO1992000763A1 (en) * | 1990-07-03 | 1992-01-23 | Akzo N.V. | Immunoreactive compound |
| EP0671412A1 (de) * | 1990-11-30 | 1995-09-13 | Asahi Glass Company Ltd. | Das Einwandern von Krebszellenhemmende Peptide und Hemmer der Krebsmetastasieurung |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0602290B1 (de) * | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung |
| EP0802798A1 (de) * | 1994-02-23 | 1997-10-29 | Chiron Corporation | Verfahren und zusammensetzungen zur verlängerung der serumhalbwertzeit von therapautika |
| AU2823495A (en) * | 1994-06-09 | 1996-01-04 | Houston Biotechnology Incorporated | Methods and compositions for modulation of wound healing |
| US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| WO1997034631A1 (en) * | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
| ES2213899T3 (es) * | 1997-04-29 | 2004-09-01 | Amersham Health As | Agentes de contraste utilizados en tecnicas de formacion de imagen en base a la luz. |
-
1998
- 1998-11-10 GB GBGB9824632.5A patent/GB9824632D0/en not_active Ceased
-
1999
- 1999-11-10 DE DE69937899T patent/DE69937899T2/de not_active Expired - Fee Related
- 1999-11-10 WO PCT/GB1999/003747 patent/WO2000027435A1/en active IP Right Grant
- 1999-11-10 AT AT99954209T patent/ATE382370T1/de not_active IP Right Cessation
- 1999-11-10 US US09/831,534 patent/US7105160B1/en not_active Expired - Fee Related
- 1999-11-10 ES ES99954209T patent/ES2299268T3/es not_active Expired - Lifetime
- 1999-11-10 EP EP99954209A patent/EP1128847B1/de not_active Expired - Lifetime
- 1999-11-10 AU AU10627/00A patent/AU1062700A/en not_active Abandoned
- 1999-11-10 EP EP07075275A patent/EP1808155A3/de not_active Withdrawn
-
2006
- 2006-07-24 US US11/492,187 patent/US20060263375A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000027435A1 (en) | 2000-05-18 |
| US7105160B1 (en) | 2006-09-12 |
| GB9824632D0 (en) | 1999-01-06 |
| EP1808155A3 (de) | 2007-10-31 |
| DE69937899D1 (de) | 2008-02-14 |
| EP1128847A1 (de) | 2001-09-05 |
| ES2299268T3 (es) | 2008-05-16 |
| EP1128847B1 (de) | 2008-01-02 |
| DE69937899T2 (de) | 2008-12-24 |
| AU1062700A (en) | 2000-05-29 |
| US20060263375A1 (en) | 2006-11-23 |
| EP1808155A2 (de) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69937899D1 (de) | Antikörper-serumprotein hybride | |
| KR910001057A (ko) | 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도 | |
| AU6264686A (en) | Antibody complexes of hapten-modified diagnostic or therapeutic agents | |
| AU563356B2 (en) | Conjugate of enzyme and antibody | |
| DE69434725D1 (de) | Zell- und Serumproteinanker und Konjugate | |
| AU7366687A (en) | Coupling agents for radiolabeling proteins | |
| DE69033705D1 (de) | Hybride immunglobuline | |
| DE69020007T2 (de) | Vernetzte Antikörper und Verfahren zu ihrer Herstellung. | |
| DE69434384D1 (de) | Metalkomplexbildner | |
| NO971059D0 (no) | Modifiserte human-C3-proteiner | |
| GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
| DK1167389T3 (da) | Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf | |
| IN172885B (de) | ||
| ATE122723T1 (de) | Retinoblastoma-genprodukt-antikörper und deren verwendungen. | |
| EP1191096A4 (de) | Neues protein und dessen dns | |
| FI971879A0 (fi) | Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi | |
| BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |